Sensitivity and specificity for anti-EBV IgA antibodies, applied to prevalent NPC and healthy controls from Taiwan
| IgA Marker | Sensitivity for prevalent NPCa | Specificity in healthy, community controls |
|---|---|---|
| Viral capsid antigen (VCAp18) | 78.9 | 49.3 |
| Early prevalent disease | 76.1 | |
| Late prevalent disease | 81.3 | |
| Epstein–Barr nuclear antigen (EBNA1) | 92.3 | 80.0 |
| Early prevalent disease | 95.5 | |
| Late prevalent disease | 89.3 | |
| Early antigen (Ead_p47) | 43.0 | 81.3 |
| Early prevalent disease | 38.8 | |
| Late prevalent disease | 46.7 | |
| Early antigen (EAp138) | 47.9 | 82.7 |
| Early prevalent disease | 38.8 | |
| Late prevalent disease | 56.0 | |
| Combined VCAp18 + EBNA1 ELISA | 99.3 | 32.0 |
| Early prevalent disease | 100 | |
| Late prevalent disease | 98.7 |
NOTE: Early disease, WHO stage I/II; late disease, WHO stage III/IV.
↵aThe percentages are based on a threshold value for determining a positive result of ≥1.0.